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Abstract
Background: CEA is a tumor-associated antigen abundantly expressed on several cancer types,
including those naturally refractory to chemotherapy. The selection and characterization of human
anti-CEA single-chain antibody fragments (scFv) is a first step toward the construction of new
anticancer monoclonal antibodies designed for optimal blood clearance and tumor penetration.
Methods: The human MA39 scFv, selected for its ability to recognize a CEA epitope expressed
on human colon carcinomas, was first isolated from a large semi-synthetic ETH-2 antibody phage
library, panned on human purified CEA protein. Subsequently, by in vitro mutagenesis of a gene
encoding for the scFv MA39, a new library was established, and new scFv antibodies with improved
affinity towards the CEA cognate epitope were selected and characterized.
Results: The scFv MA39 antibody was affinity-maturated by in vitro mutagenesis and the new scFv
clone, E8, was isolated, typed for CEA family member recognition and its CEACAM1, 3 and 5
shared epitope characterized for expression in a large panel of human normal and tumor tissues
and cells.
Conclusion: The binding affinity of the scFv E8 is in a range for efficient, in vivo, antigen capture in
tumor cells expressing a shared epitope of the CEACAM1, 3 and 5 proteins. This new
immunoreagent meets all criteria for a potential anticancer compound: it is human, hence poorly
or not at all immunogenic, and it binds selectively and with good affinity to the CEA epitope
expressed by metastatic melanoma and colon and lung carcinomas. Furthermore, its small
molecular size should provide for efficient tissue penetration, yet give rapid plasma clearance.
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Background
The construction of libraries of recombinant antibody
fragments that are displayed on the surface of filamentous
phage, and the selection of phage antibodies against target
antigens, have become an important technological tool in
generating new monoclonal antibodies for research and
clinical applications. Human antibodies obtained by this
method do not induce harmful immune response in
patients, in comparison with murine monoclonal anti-
bodies produced by the classic hybridoma techniques.
Moreover, the affinity of selected antibodies can be
improved through construction of mutant antibody
libraries giving clones with greater affinity. Thus, naïve or
semi-synthetic human antibody libraries can be used in
the search for specific antibodies without immunization
with respective antigens.
The carcinoembryonic antigen (CEA) is an oncofetal glyc-
oprotein, containing 50% carbohydrate with a molecular
weight of approximately 200 kDa [1], overexpressed in
several tumor types of epithelial origin and known as an
important and extensively used clinical tumor marker for
colorectal and other carcinomas [2-4]. In tumor patients,
with growth of the tumor mass, more CEA is accumulated
in the blood. Therefore, the CEA serum levels can be used
to monitor recurrent disease in the post-surgical surveil-
lance of colorectal cancer [5], but not to localize the
lesions.
The use of labeled monoclonal antibodies that target a
tumor-associated antigen was first described by Golden-
berg [6]. In several recent studies, anti-CEA antibodies
were used to localize CEA-expressing solid tumors.
Murine (CEA)-specific monoclonal antibodies were suc-
cessfully tested in animals for their capacity to accurately
localize tumors formed by human colorectal carcinoma
cell lines with various levels of CEA expression and, as a
result, their use is foreseen in radioimmunoguided sur-
gery (RIGS) [7]. The immunoscintigraphy analysis, with
an anti-CEA monoclonal antibody fragment labeled with
99mTc, in patients with colorectal carcinoma recurrence,
was evaluated as an effective method for early detection of
pelvic and extrahepatic abdominal metastases [8]. A Phase
I clinical trial was reported for RIGS with recombinant
phage-selected scFv anti-CEA antibody fragment to CEA
[9]. Rapid blood clearance, good tumor penetration, the
lack of significant toxicity, and relatively simple produc-
tion in bacteria, make such antibodies suitable for clinical
practice.
We describe in this paper the selection of a new anti-CEA
single-chain antibody fragment, MA39, from an ETH-2
synthetic antibody library [10]. This antibody recognizes
human CEA protein in ELISA, Western blot and flow
cytometry. The single-chain antibody was affinity-matu-
rated by mutagenesis in vitro. The dissociation constant of
the new maturated anti-CEA E8 antibody (1.39 × 10-8)
was decreased more than 10-fold compared to the origi-
nal MA39 (1.71 × 10-7). The specificity of E8 scFv was
assessed by flow cytometry on a broad panel of human
cells and BOSC23 cells, ectopically expressing members of
the CEACAM protein family, and by immunohistochemi-
cal staining of tumor and normal human tissues.
Methods
Bacterial strains
Bacterial strains TG1 (supE hsd∆5  thi  ∆(lac-proAB) F'
[traD36  proAB+  lacIqlacZ∆M15]) and DH5αF' (supE44
∆lacU169 (φ80 lacZ∆M15) hsdR17 recA1 endA1 gyrA96 thi-
1 relA1 F' [traD36 proAB+ lacIqlacZ∆M15]) were used for
phage antibody production. The HB2151 bacterial host
strain (nalr thi-1  ara  ∆(lac-proAB) F' [proAB+  lacIq
lacZ∆M15]) was used for large-scale soluble antibody pro-
duction.
CEA biotinylation
One hundred µg of CEA (Sigma, St Louis, MO) were dis-
solved in 0.9 mL of PBS and incubated with 100 µL of
biotinamidohexanoic acid N-hydroxysuccinimide ester
(B2643, Sigma) at a concentration of 2.2 mg/mL in 2.8%
DMSO at room temperature (RT); after 1 h incubation, 50
µL of 1 M NaHCO3, pH 9, were added to the protein. Sam-
ple was dialyzed against PBS overnight (ON) at 4°C.
ETH-2 library and phage antibody selection
The ETH-2 synthetic human recombinant antibody
library consists of a high array (more than 109 antibody
combinations) of single-chain variable fragment antibod-
ies (scFv) displayed on the surface of filamentous phage.
It was built by random mutagenesis of the CDR3 of only
three antibody gene germline segments (DP47 for the
heavy chain, DPK22 and DPL16 for the light chain). The
diversity of the heavy chain was created by randomizing
four to six positions, replacing the pre-existing 95 to 98
positions of the CDR3. The diversity of the light chain was
created by randomizing six positions (96 to 101) in the
CDR3 of this chain (for details of ETH-2 library see [10]).
An aliquot of the ETH-2 library containing approximately
1012 transducing units (TU) was incubated with 2.5 mL of
50 nM biotinylated CEA in 2% milk in PBS (MPBS) for 2
h at RT. The bound phage was captured by using strepta-
vidin-coated M-280 Dynabeads (112.05, Dynal, Oslo,
Norway) according to manufacturer's instructions,
washed 15 times with TPBS (0.1% Tween 20 in PBS) and
15 times with PBS using a magnetic device. Bound phages
were eluted with 500 µL of 100 mM triethylamine and the
solution was immediately neutralized by adding 0.5 mL
of 1 M Tris-HCl (pH 7.4). Eluted phages were used toBMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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infect E.coli TG1 cells and amplified for the next round of
panning.
Design and construction of first maturation library
For the construction of MA39 mutated library, the gene of
MA39 scFv clone selected from the ETH-2 library was used
as template for PCR amplification (Figure 1). Mutated
scFv gene fragments were generated by PCR amplification
with primers KM144-KM143 and KM148-KM145 (Table
1), introducing random mutations in CDR3 regions of
heavy or light chains with low frequency. The KM144 and
KM145 oligonucleotides were synthesized with partial
substitution by a four-nucleotide mixture on each posi-
tion corresponding to CDR3 region with a frequency of
10% (central underlined part of the sequence) (MWG Bio-
tech, Ebersberg, Germany). In addition, the antibody frag-
ment containing CDR3 of the heavy chain was amplified
using KM143 together with KM149, KM150, KM151 and
KM152, including from two to three NNS random triplets
at the 5' and 3' sites of CDR3-encoding sequence. Missing
scFv antibody fragments were amplified with primers
KM148-KM157 and KM158-KM143 for HC and LC,
respectively. The oligonucleotides KM157 and KM158
were designed to obtain overlapping fragments allowing
assembly of a full-length mutated scFv gene, as indicated
in Figure 1. In each case, two resulting PCR fragments
were agarose-purified and assembled by 5 cycles of PCR
without primers and then amplified with external primers
KM148-KM143. The final PCR product was agarose-puri-
fied, digested with restriction enzymes NcoI and NotI, and
cloned into the plasmid of pDN332, containing FLAG tag
sequence and a 6×His tag for protein purification [11],
which was also digested with NcoI and NotI. A ligation
mixture was used to transform the DH5αF'-competent
cells to get an initial maturation library with a complexity
of 2.5 × 106 scFv members.
Second maturation library
For construction of CP1 mutated library, the gene of the
CP1 scFv clone, selected from the first maturation library,
was used as template for PCR amplification (Figure 1).
CP1 clone was amplified with pairs of primers KM148-
KM170, KM169-KM172, KM171-KM174  and KM173-
KM143 (Table 1). Fragments amplified with underlined
primers were mutated by error-prone PCR, introducing
mutations in the corresponding fragment with a fre-
quency of 1% to 2%. These primers were designed to
amplify scFv gene regions corresponding to the CDR1 and
CDR2 regions of both chains, as shown in Figure 1. PCR
was performed in final volume 100 µL using Taq polymer-
ase (Promega, Madison, WI) in presence of 6.5 mM
MgCl2, 0.5 mM MnCl2, 1 mM dCTP, 1 mM dGTP, 1 mM
dTTP, 0.2 mM dATP, and 0.1 mM dITP. The resulting four
fragments were agarose gel-purified, and assembled to
generate a full-length mutated scFv gene by five cycles of
PCR-like amplification without primers. The KM143 and
KM148 external primers were then added and the reaction
was cycled another 25 times. The gel-purified PCR prod-
uct was cut with NcoI and NotI, and ligated into the plas-
mid of pDN332, also digested with NcoI and NotI. The
maturation library had a complexity of 1.7 × 107 scFv
clones. After two rounds of selection, the phage pool was
amplified and single-chain DNA was purified by PEG/
NaCl precipitation and phenol extraction [12]. All proce-
Table 1: Oligonucleotide primers used for construction of mutant libraries for affinity maturation of anti-CEA MA39 scFv antibody. 
Wobble symbol N means G or A or T or C, symbol S means G or C. In underlined part of oligonucleotides KM144 and KM145, each 
base was replaced with mixture of G/A/T/C at a frequency of 10%.
KM144 5'-TGTGCGAAAAGTAATGAGTTTCTTTTTGACTACTGGGGC-3'
KM145 5'-TCCGCCGAATACCACATAGGGCAACCACGGATAAGAGGAGTTACAGTAATAGTCAGCC-3'
KM149 5'-GTATATTACTGTGCGAAANNSNNSNNSAGTAATGAGTTTCTTNNSNNSNNSTTTGACTACTGGGGCCAG-3'
KM150 5'-GTATATTACTGTGCGAAANNSNNSAGTAATGAGTTTCTTNNSNNSNNSTTTGACTACTGGGGCCAG-3'
KM151 5'-GTATATTACTGTGCGAAANNSNNSNNSAGTAATGAGTTTCTTNNSNNSTTTGACTACTGGGGCCAG-3'
KM152 5'-GTATATTACTGTGCGAAANNSNNSAGTAATGAGTTTCTTNNSNNSTTTGACTACTGGGGCCAG-3'
KM148 5'-CTATTGCCTACGGCAGCCGCTGGA-3'
KM157 5'-TTTCGCACAGTAATATACGG-3'
KM158 5'-TATGTGGTATTCGGCGGA-3'
KM143 5'-GTCATCGTCGGAATCGTCATCTGC-3'
KM169 5'-GGTGGTAGCACATACTACGCA-3'
KM170 5'-GGAATTGTCTCTGGAGATGGTGA-3'
KM171 5'-TCGTCTGAGCTGACTCAGGAC-3'
KM172 5'-GCATGTGATCCTGACTGTCTG-3'
KM173 5'-CTCCAGCTCAGGAAACACAGCTT-3'
KM174 5'-AGCCTCATCTTCCGCCTGAG-3'
KM252 5'-GAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGC-3'
KM253 5'-GAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGC-3'BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
Page 4 of 15
(page number not for citation purposes)
Scheme of mutagenesis in vitro Figure 1
Scheme of mutagenesis in vitro. First maturation library was generated by using partially degenerated oligonucleotides. 
Second maturation library was constructed by error-prone PCR method.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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dures of mutagenesis, assembly and cloning were
repeated, yielding a library with a complexity of 1.6 × 106
independent scFv clones.
Correction of TGA codon for soluble scFv production
Mutant scFv genes from E1, E2, E3, E4, E6, E8, E13, E14,
and E15 clones were amplified with KM148-KM253 and
KM252-KM143 primers (Table 1), thus, changing TGA
into TGG codon, as in original MA39 sequence, reassem-
bled, and cloned in the antibody-expressing phagemid
and transformed into HB2151 bacteria.
Phage pool amplification and small scale scFv production
DH5αF' or TG1 bacterial cells infected with eluted phage
were plated on agar-plates containing 100 µg/mL Ap
(Sigma) and 1% glucose. Next day, a 50 µL aliquot of
scrapped cells was incubated in 40 mL of LB (100 µg/mL
Ap, 1% glucose) till OD600 = 0.2 with shaking at 37°C.
Cells were spun down and resuspended in 40 mL of LB
(100 µg/mL Ap), and then infected with M13K07 helper
phage with a multiplicity of 20:1. Bacterial culture was
incubated for a further 2 h at 37°C. Twenty µg/mL of Km
(Sigma) were added to the bacterial culture, which was
incubated on a shaker ON at 32°C. The rescued phages
were PEG/NaCl-purified.
Supernatants of single phages were prepared as follows:
infected individual TG1 colonies were inoculated in 150
µL 2×TY (100 µg/mL Ap, 1% glucose) in 96-well plates,
incubated for 2 h at 37°C and superinfected with 109 pfu
M13K07 helper phage in 25 µL 2×TY. After 30 min, plates
were centrifuged at 1800 g for 10 min and bacterial pellet
was resuspended in 200 µL 2×TY (100 µg/mL Ap, 20 µg/
mL Km) and incubated on a shaker ON at 37°C.
For soluble scFv preparation, colonies were grown for 2 h
at 37°C in 180 µL 2×TY (100 µg/mL Ap, 0.1% glucose) in
96-well plates and inducted with 50 µL 2×TY, containing
6 mM IPTG. On the following day, the plates were spun
down at 1800 g for 10 min and the supernatants contain-
ing soluble scFvs were recovered and tested for specific
CEA recognition.
ELISA
Streptavidin-coated 96-well plates (Roche Diagnostics,
Indianapolis, IN) were incubated ON at RT with 50 µL of
biotinylated CEA (1 µg/mL) in PBS. After discarding CEA
solution the plates were blocked with MPBS for 1 h at
37°C and rinsed with TPBS. One hundred µL of soluble
scFvs in blocking buffer were added to each well and incu-
bated for 1 h at RT. The plate was washed and incubated
for 2 h with a freshly prepared mixture consisting of an
anti-FLAG M2 (12.5 µg/mL, F3165, Sigma) and an anti-
mouse HRP-conjugated antibody (22 µg/mL, Dako, Glos-
trup, Denmark). The immunoreaction was developed
using 3,31-5,51-Tetramethylbenzidine (soluble BM blue
POD substrate, Roche Diagnostics), stopped by adding 1
M sulfuric acid and read with an ELISA reader (Model 680
microplate reader, Biorad, Hercules, CA). Results were
expressed as A = A(450 nm)-A(620 nm).
Alternatively, ELISA was performed by coating ELISA plate
with 10 mg/mL of biotin-free CEA in 50 mM NaHCO3,
pH 9.6. The phage antibody clones were tested using
either of two secondary antibodies: an anti-FLAG HRP-
conjugated (A8592, Sigma) or an anti-M13 HRP-conju-
gated secondary antibody (27-9421-01, Amersham Bio-
sciences, Uppsala, Sweden).
Normalization of soluble scFv quantities was performed
by coating ELISA plate with 2 µg/mL of a monoclonal
anti-poly Histidine antibody (H1029, Sigma). Serial dilu-
tions from 1/1000 to 1/27000 of each soluble scFv were
applied, and ELISA was developed using an anti-FLAG
HRP-conjugated secondary antibody.
Soluble scFv purification
The MA39 and E8 antibody clones were cultured for large-
scale scFv production. HB121 E. coli infected cells were
cultured at 30°C in LB containing 100 µg/mL Ap and
0.1% glucose till OD600 = 0.5. After induction of antibody
expression by adding 1 mM IPTG to culture, cells were
incubated for another 3 h at 30°C. Periplasmic extracts
were prepared by resuspending the bacterial pellet in 1/20
the original volume of 30 mM Tris, pH 7.0, 20% sucrose
and 1 mM EDTA. After incubation for 20 min on ice, the
debris was removed by centrifugation and supernatants
(periplasmic fraction) were filtered (0.2 µm, Millipore,
Bedford, MA). His-tagged scFv fragments were purified by
immobilized metal affinity chromatography using Ni2+-
nitriloacetic acid agarose (Qiagen, Madison, WI). ScFv
fragments were eluted with 250 mM imidazole in PBS,
dialyzed against PBS, tested for specific antigen recogni-
tion and stored at -80°C in small aliquots.
Surface Plasmon Resonance (SPR)
Carcinoembryonic antigen (US Biological, Swampscott,
MA) was immobilized on a CM5 sensor chip according to
standard amine coupling procedure, using amine cou-
pling kit (Biosense, Milan, Italy). Briefly, the car-
boxymethylated dextran-coated surface was activated by a
7-min injection of a solution containing 200 mM N-ethyl-
N'dimethylaminopropylcarbodiimide (EDC) and 50 mM
N-hydroxysuccinimide (NHS) followed by a 50-second
injection of CEA (20 µg/mL in 10 mM sodium acetate, pH
3.7 adjusted with HCl). A continuous flow of HBS buffer
(10 mM Hepes, 0.15 M NaCl, 3.4 mM EDTA and 0.005%
surfactant P20, pH7.4) at 5 µL/min was maintained and
capping of unreacted sites was achieved by injecting 1 M
ethanolamine, pH 8.5. The final immobilization responseBMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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was 421 Resonance Units (RU) equal to 0.421 ng/mm2.
Blank surfaces were obtained in the same manner as
kinetic surfaces, except that no protein was injected.
Sensorgrams for kinetic measurements were generated by
the injection of soluble scFv (at 5 concentrations ranging
from 62.5 nM to 4.5 µM) in HBS at a flow rate of 30 µL/
min. Kinetic data were collected in duplicate for each anti-
body concentration. Association and dissociation times
were 120 and 180 seconds, respectively. The chip was
regenerated by injection of repeated pulses of 100 mM
NaOH until the difference between the baselines before
and after NaOH injection was less than 10 RU. Biosensor
data were collected, modeled and fitted by means of BIAe-
valuation 3.1 software (Biacore, Uppsala, Sweden). The
quality of the fitted data was evaluated by comparison
between calculated and experimental curves (residual val-
ues) and by the magnitude of the chi2 parameter.
Specificity test
The CEACAM specificity test was performed by flow
cytometry on BOSC23 cells transiently transfected with
plasmids encoding for single CEACAM family members
(Genovac, Freiburg, Germany). Briefly, 106  cells were
seeded in 6-well plates and transfected with Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer's instructions. After ON incubation, the
cells were collected, washed and resuspended in 200 µL
PBS, 1% FCS at a concentration of 107 cells/mL. The flow
cytometry reaction was carried out in 96-well plates in
three steps using about 105 cells per well. Cell suspensions
were first incubated with 25 µg/mL of primary scFv anti-
body; then, with 10 µg/mL of a secondary mouse anti-
FLAG antibody (F3165, Sigma); and finally stained with a
PE-conjugated anti-mouse antibody (550589, BD
Pharmingen, Erembodegem, Belgium). Cells were incu-
bated for 30 min at 4°C for each step, and washed with
PBS containing 1% FCS. After final washing, cells were
resuspended in PBS for acquisition and analysis using a
FACSCalibur instrument with Cell Quest software (BD
Biosciences, Erembodegem, Belgium). An irrelevant anti-
glucose oxidase scFv antibody (enzyme not present in
mammals) was used as negative control [13].
CEA determination on cells
The expression of CEA on the surface of cells was quanti-
fied by using specific scFv in flow cytometry investigations
on a consistent panel of human cell lines which include
CCRF-CEM and JURKAT (acute lymphoblastic leukemia),
GLC4 and H69 (small cell lung carcinoma), K-562
(chronic myelogenous leukemia), MCF7 (breast adeno-
carcinoma), RPMI8226 (myeloma), HT29 and LoVo
(colorectal carcinoma), U937 (monocytic lymphoma),
KB3.1 (cervical carcinoma), THP-1 (moncytic leukemia),
HL-60 (promyelocytic leukemia), MV-4-11 (B myelo-
monocytic leukemia), Mel.1 and Mel.2 (melanoma cell
lines prepared from primary melanoma specimens), and
Mel.3 and Mel.4 (metastatic melanoma cell lines prepared
from melanoma metastasis samples). HF, adult primary
fibroblasts, (CD4+) PBMC subpopulation, purified
monocytes (CD14+), granulocytes and neutrophils were
also included in this study.
Adherent cells in exponential phase of growth were first
trypsinized (we verified that CEA antigen is not sensitive
to trypsin treatment), then collected, carefully washed in
PBS 1% BSA and pelletted. About 2.5 × 105 cells were
resuspended with 50 µL PBS, 1% BSA containing 5 µg/mL
of primary scFv antibody and incubated for 1 h at RT. After
several washings, cells were resuspended for 1 h at 4°C in
a PBS, 1% BSA solution containing 10 µg/mL of an anti-
FLAG mouse antibody (Sigma) and after washings, cells
were incubated with 6 µg/mL of an FITC-goat anti-mouse
IgG (#31541, Pierce, Rockford, IL) for 30 min at 4°C. An
irrelevant antibody directed to glucose oxidase was used
as negative control. After staining, the cell samples were
washed, maintained at 4°C and immediately analyzed by
FACScan (Becton, Dickinson and Company, Franklin
Lakes, NJ) equipped with 15 nW argon laser. Fluorescence
compensation was determined using samples stained
with anti-glucose oxidase scFv and goat FITC-conjugated
anti-mouse secondary antibody.
To study CEA distribution by scFv MA39, about 2 × 105
LoVo cells were spun down onto glass slides (Shandon,
Pittsburgh, PA) or attached to poly-L-lysine-covered glass
chamber slides (Labtek, Campbell, CA), fixed in 80%
methanol solution for 10 min at 4°C. After soaking in
TBS, the slides were treated for 10 min with peroxidase
block solution (Dako EnVision System HRP, AEC),
washed with RPMI, 10% FCS and incubated with 100 µL
cell culture supernatant containing approximately 2.5 µg/
mL scFv MAb MA39. Staining was performed by the per-
oxidase-antiperoxidase (PAP) method (Dako), counter-
staining with Mayer hematoxyline (BDH, Milan, Italy).
Western blot
Serial dilutions of purified CEA were fractionated by SDS/
PAGE and transferred onto a nitrocellulose membrane.
The membrane was blocked in PBS with 0.05% Tween 20
containing 5% non-fat dry milk. After washing, the mem-
brane was incubated with soluble scFv antibody at 4°C
ON, washed and then specific binding with scFv was
detected by incubation for 1 h at 37°C with an anti-FLAG
AP-conjugated antibody (A9469, Sigma) in 5% milk/PBS.
DNA characterization of scFv antibodies
CEA-positive clones were analyzed by PCR amplification
with primers KM143 and KM148. Agarose gel electro-
phoresis of PCR products confirmed integrity of scFv cod-BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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ifying inserts. Nucleic acid sequencing of the clones was
carried out on an automated DNA sequencer Applied Bio-
systems Prism Dyes Terminator Sequencing Kit (Perk-
inElmer, Boston, MA) using KM143 and KM148 primers.
Confocal laser scanning microscopy (CLSM) analysis
Melanoma metastatic cells (Mel.3) were grown on glass
slides, and, after washing with PBS, incubated for 1 h at RT
with 5 µg/µL of soluble scFv E8. At the end of incubation,
the cells were washed with PBS and incubated for 30 min
at 4°C with 2 µg/µL anti-FLAG (Sigma). Binding was
detected with an FITC-conjugated anti-mouse antibody
(Pierce) and then fixed with 4% paraformaldehyde for 5
min at RT. For CLSM analysis, coverslips were washed five
times in PBS and mounted in buffered PBS-glycerine (1:1
v/v) solution; observations were performed using a Leica
TCS SP2 spectral confocal microscopy equipped with
argon-helium neon (Ar-HeNe) lasers and right filters for
FITC fluorescence. Images were processed using LCS
(Leica Microsystems, Heidelberg GmbH, Germany) and
Photoshop (Adobe Systems Inc. Mountain View, CA) soft-
ware programs.
Immunohistochemistry
Immunohistochemistry studies were conducted on cryo-
static sections of human lung cancer, melanoma and var-
ious normal tissues (TriStar Technology Group, LLC,
Rockville, MD). Slides were processed according to stand-
ard protocols and binding revealed using Vectastain ABC
(Vector Laboratories, Burlingame, CA). Briefly, the cryo-
static tissue sections were fixed for 10 min with acetone at
-20°C and endogenous peroxidase was blocked with
0.2% HCl in ethanol for 15 min. After two washes with
TBS, slides were blocked with normal horse serum and
then incubated for 2 h at RT (with 10 µg/mL of scFv E8).
Slides were then washed and incubated for 1 h at RT with
10 µg/mL anti-FLAG monoclonal antibody (Sigma). After
further washing, slides were incubated with avidin-biotin-
peroxidase complex for 30 min. Finally, DAB substrate
(Vector Laboratories) was added and the reaction was
stopped after 5 min by washing in tap water. Counter-
staining was performed with Mayer's hematoxylin (Vector
Laboratories) for 10 seconds. Negative controls included
slides incubated with secondary antibody alone. The
staining intensity was evaluated by microscopic observa-
tion and graded from strong (+++) to no staining (-).
Results
Selection and specificity of MA39 scFv
In order to isolate phage-displayed specific antibodies, an
aliquot of the human synthetic ETH-2 library containing
approximately 1 × 1012 TU was panned on biotinylated
CEA, as described in Materials and Methods. After three
rounds of selection, characterized by a progressive growth
of output phage titer, several CEA-specific scFvs were iso-
lated, since no cross-reactivity with streptavidin-coated
plates was observed (data not shown). MA39, a phage
antibody clone, one of the most reactive in ELISA, was cul-
tured and quantities of purified scFv were produced for
further investigation.
Flow cytometry, biochemical and immunohistochemical
studies indicate that scFv MA39 recognizes a genuine CEA
epitope in its extracellular domain. In fact, MA39 binds to
intact living human colon carcinoma LoVo cells (Figure
2A); in Western blot it recognizes a 200 kDa molecule of
purified CEA antigen, and LoVo cellular extract (Figure
2B); it also stains human adenocarcinoma xenograft in
mouse (Figure 2C).
Maturation of anti-CEA scFv antibody
The first maturation library was constructed by introduc-
ing random mutations into CDR3 regions of heavy or
Recognition of CEA by MA39 antibody Figure 2
Recognition of CEA by MA39 antibody. A. Immunode-
tection of CEA in LoVo cells by MA39 scFv (left slide). The 
same slide preparation incubated with irrelevant anti-glucose 
oxidase (a protein not present in mammals) scFv antibody 
(anti-G.O., right slide). B. Biochemical patterns of the MA39 
on purified CEA (lane 1) and LoVo cellular extract (lane 2). 
Lanes 3 and 4 show the reactivity of identical proteins with 
irrelevant anti-G.O. scFv. C. Staining of cryosections from 
human colon carcinoma xenograft in mouse. Commercially 
available anti-CEA antibody and irrelevant anti-G.O. antibod-
ies were used as positive and negative controls, respectively.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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light chains with low frequency, or by inclusion of 2–3
NNS random triplets at the 5' and 3' ends of heavy chain
CDR3 of the MA39 scFv gene, as described in Materials
and Methods (Figure 1). The library was affinity-selected
three times against CEA protein. Phage random clones
were prepared and tested in ELISA (data not shown).
Clones with higher reactivity and the original MA39 scFv
were sequenced to confirm mutation events. Figure 3
shows all sequences. There are only substituting muta-
tions, but no insertions among the sequenced mutated
genes. Unexpectedly, numerous selected phage clones (9
out of 12) harbor TGA, or TAG stop codon mutations.
Bacterial strain DH5αF', used for phage amplification,
suppresses TAG codon with glutamine aa residue. We find
Identified scFv antibody sequences Figure 3
Identified scFv antibody sequences. Peptide sequences are reported in single-letter code. Amino acids in the mutated 
clones identical to parental MA39 are represented by a dash. CP1 – B18 and E1 – E16 groups of clones were isolated from first 
and second maturation libraries, respectively. Letters "q" and "t" correspond to glutamine and tryptophan amino acids in sup-
pressed nonsense codons.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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that this strain also suppresses the TGA codon. In order to
test scFv antibody reactivity, ELISA was performed with
phage supernatants and developed using anti-phage sec-
ondary antibodies. It excluded any influence of an incom-
plete antibody fragment participation in assay,
confirming that full-length scFv antibodies fused with pIII
protein in all these cases are displayed on the phage sur-
face, implying suppression, probably with low efficiency,
of TGA stop codons. Additionally, we also see the appear-
ance of polar amino acids like arginine and serine,
together with proline in amino-terminal part of light
chain, in regions not undergoing the mutagenesis process.
Among first generation clones, CP1, which gained a muta-
tion in CDR3 segment of light chain (P→A), was chosen
for the next round of mutagenesis and maturation
because of its reactivity. The CP1 gene contains a TGA
codon within the heavy chain DNA fragment. We had no
idea how common a phenomenon is the accumulation of
nonsense codons that pull down the expression of phage
antibodies during the selection process. It probably occurs
when a high expression level of certain antibodies is toxic
for bacteria. We decided to directly maturate the CP1 gene
without TGA stop codon correction. The CP1 gene was
mutated by error-prone PCR as described in Materials and
Methods. This method permits the introduction of ran-
dom mutations with efficiency up to 1% to 2%, using PCR
amplification, performed with rising concentrations of
Mg2+, lowering concentrations of dATP and by including
dITP and Mn2+ in reaction mixture [14,15]. Mutations
were introduced in scFv gene regions corresponding to
CDR1 and CDR2 zones of both chains (Figure 1). A sec-
ond maturation library was selected twice against CEA
protein, then single-stranded DNA was purified from
phage pool and subjected to repeated error-prone muta-
genesis; it was subsequently panned against target protein.
A number of random clones (E1-E16) from last phage
pool were tested in ELISA and sequenced.
Production of soluble scFv antibodies
In order to analyze the relative reactivity of newly selected
anti-CEA scFv mutants (the presence of TGA or TAG tri-
plets in some phage clones with unknown suppression
levels of stop codons prevents a correct analysis of anti-
Table 2: Kinetic values of parental and affinity-matured single chains
ScFv kon (+/- SE) koff (+/- SE) KD
MA39 2.08E+04 (4.39E+02) 3.57E-03 (8.64E-05) 1.71E-07
E8 1.98E+05 (3.36E+03) 2.74E-03 (5.32E-05) 1.39E-08
ELISA reactivity of original and mutated anti-CEA antibodies Figure 4
ELISA reactivity of original and mutated anti-CEA antibodies. Equal quantity of the soluble scFv antibodies were 
assayed on CEA-coated plates. Bound scFvs were developed by using anti-FLAG secondary antibody. Results are expressed as 
A = A405-A620. Data reported are the average values of two independent assays.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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body reactivity), several mutant scFv genes from E1, E2,
E3, E4, E6, E8, E13, E14, E15 and E16 clones were ampli-
fied with KM148-KM253 and KM252-KM143 primers.
The genes were reassembled and cloned into phagemid
vector, thus reconstructing the original TGG codon as in
parental MA39 gene. Soluble scFvs were produced in
HB2151 bacterial strain, as described in Materials and
Methods, and normalized by ELISA on anti-polyhistidine
antibody-coated plates. Equal quantities of soluble anti-
bodies were tested by ELISA for their capacity to bind CEA
protein (Figure 4). The E8 scFv, having higher reactivity,
was prepared together with MA39 in large amounts for
measurement of their affinity and investigation of specifi-
city.
Comparison of original and affinity-maturated scFv 
antibodies
Plasmon resonance studies with BiacoreX provided quan-
titative measures of scFv-antigen binding and dissociation
kinetics. The KD was calculated on the basis of the meas-
ured ka and kd rate constants by using a 1:1 Langmuir
model for simple bimolecular interactions (Biaevaluation
3.0 software, Biacore International, Uppsala, Sweden).
Table 2 reports the kinetic values of the parental and affin-
ity-matured scFvs, determined on the CEA-coated chip.
The original MA39 antibody has over 10 times lower
affinity with the antigen, compared to E8, due to a slower
association rate. The maturation process did not affect the
dissociation rate.
A direct comparison of the CEA binding ability of MA39
and the maturated E8 scFvs was also assessed by flow
cytometry analysis on a metastatic melanoma cell line
(Mel.3). Results show that the increase in affinity is
reflected in a significant fluorescent profile shift in the
case of the E8 scFv (Figure 5A).
Western blot with serial dilutions of human CEA protein
was developed with equal quantities of original and mat-
urated antibodies (Figure 5B). The intensity of the devel-
oped color was increased when affinity-maturated scFv E8
was used for staining.
Recognition of CEACAM proteins, human cells and human 
tumors by E8 scFv
The affinity-maturated scFv E8 was tested for binding on
eight different transiently transfected cell lines, each
expressing a different member of the CEACAM protein
family. According to this study the scFv antibody is reac-
tive with CEACAM1 (BGP, CD66a), CEACAM3 (CGM1,
CD66d) and CEACAM5 (CEA, CD66e) (Figure 6). This
CEACAM recognition pattern of scFv E8 was also verified
on a large panel of human cells which included 18 tumor
cell lines, adult primary fibroblasts, PBMC subpopula-
tions CD4 and CD14 and neutrophils (Table 3). As shown
Comparison between MA39 and E8 antibodies Figure 5
Comparison between MA39 and E8 antibodies. A. 
Recognition of metastatic melanoma cells expressing CEA by 
MA39 and maturated E8 scFv antibodies. Significant fluores-
cence shift indicates difference in affinity of two single-chain 
antibodies. B. Western blot with serial dilutions of CEA pro-
tein was stained by using original MA39 and maturated E8 
scFv antibodies. The membranes were developed with sec-
ondary anti-FLAG AP-conjugated antibody.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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in Table 3 and partially in Figure 7A, scFv E8 strongly
reacts with melanoma metastatic cells, and to a lesser
extent, with colon carcinomas HT29 and LoVo, breast car-
cinoma MCF7, small cell lung carcinoma H69 and pri-
mary melanomas. In contrast, we see no binding with
cervical carcinoma, several human leukemias, CD4 and
CD14 subpopulations (Figure 7B) nor with human neu-
trophils. Figure 8 presents fluorescent staining of the met-
astatic melanoma cells.
We examined E8 scFv specificity by immunohistochemi-
cal staining on a large panel of samples obtained through
cryostatic sectioning of various normal human tissues,
human melanomas and lung cancers. E8 scFv specifically
binds only tumor tissue. No unspecific staining was
observed on a broad panel of human organs (Table 4, Fig-
ure 9). Weak background labeling of lung tissue was reg-
istered in one case out of nine tested. Negative control
anti-G.O. antibody showed no staining (data not shown).
Discussion
We were successful in selecting a primary single-chain var-
iable antibody fragment against the human CEA protein
from human synthetic ETH-2 scFv library. MA39 effi-
ciently stained LoVo (human colon carcinoma) cells and
human colon carcinoma xenograft in mouse, and
detected a 200 kDa protein band on Western blot per-
formed with LoVo protein extract, indicating the MA39
scFv as specific and sensitive reagent for immunochemical
studies.
Additionally, we generated two successive maturation
libraries to produce a second generation of scFv antibod-
ies with higher affinity. In several cycles of in vitro muta-
genesis, we introduced mutations with low frequency in
CDR3 of heavy and light chains, and then in CDR1 and
CDR2 regions of both chains. Analysis of mutated scFv
genes, after two rounds of mutagenesis, revealed muta-
tions that alter the primary structure of the antigen-bind-
ing sites and that also lie outside of CDR regions. These
latter mutations appear to be important for protein fold-
ing, reducing the formation of aggregates, a known limit-
Table 4: Immunohistochemical staining on cryostatic tissue 
sections
Tissue sample Positively stained/Total tested samples
Melanoma 7/34
Normal skin 0/9
Lung cancer 15/35 (8 strong)
Normal lung 1/9 (few cells)
Normal tissues/organs Negative on 29 different organs
Table 3: Flow cytometry determination of the binding level of the scFv clone, M39, and its affinity-matured variant, E8, on living/intact 
human cells. A. Stained cells: -, (0–5 %); +/-, (6–25 %); +, (26–50 %); ++, 51–75 %); +++, (76–100 %); B. Melanoma cells derived from 
characterized specimens of tumor patients; C. PBMC and specific cell subpopulations derived from blood of healthy donors. No 
differences were observed in MA39 or E8 reactivity using cells from different donors.
Cell type Tissues MA39 E8 Notes
HT-29 Colorectal adenocarcinoma + ++ A
LoVo Colorectal adenocarcinoma + ++
KB3.1 Cervical squamous cell carcinoma - -
MCF7 Breast adenocarcinoma +/- +
U937 Monocytic lymphoma - -
Mel.1 Primary melanoma +/- + B
Mel.2 Primary melanoma +/- +
Mel.3 Metastatic melanoma ++ +++
Mel.4 Metastatic melanoma ++ +++
CCFR-CEM T cell acute lymphoblastic leukemia - -
H69 Small cell lung carcinoma - +/-
Jurkat T cell acute leukemia - -
GLC4 Small cell lung carcinoma - -
K-562 Chronic myelogenous leukemia - -
RPMI8226 B lymphocyte myeloma - -
MV-4-11 B myelomonocytic leukemia - -
THP-1 Acute monocytic leukemia - -
HL-60 Acute promyelocytic leukemia - -
HF Adult primary fibroblasts - -
PBMC total - - C
CD4+ - -
CD14+ - -
Granulocytes - -
Neutrophils - -BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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ing process in the production of many recombinant
proteins, including recombinant antibodies [16]. Indeed,
gel filtration of MA39 and E8 scFv samples revealed a large
fraction of protein aggregates in MA39 preparation (data
not shown).
Sequence analysis of mutated clones after first round of
mutagenesis revealed clear acquisition of stop codons
during affinity selection, such as TAG, suppressed by
DH5αF'-suppressing bacteria, and TGA, suppressed by
natural suppression (suppression of nonsense mutation
with native, not mutant tRNA [17-22]), where UGA triplet
is decoded at a very low frequency by inserting tryptophan
residue [23]. The acquisition of stop codons and muta-
tions in non-mutagenized scFv gene regions probably
indicates a strong selective pressure in bacteria for expres-
sion of the anti-CEA antibody.
CEA is an attractive target for immunotherapeutic pur-
poses because of its expression profile, its role in tumor
progression, and its immunogenicity. However, CEA
belongs to the CD66 immunoglobulin superfamily that
comprises highly homologous molecules expressed on
several normal and transformed tissues and cells [24].
Flow cytometry investigations show that scFv E8 strongly
reacts with a shared CEACAM1, 3 and 5 epitope. While
the role of CEACAM5 has been extensively described in
tumors [4], CEACAM1 and CEACAM3 are known to be
expressed on human neutrophils, where their surface
expression is increased following neutrophil activation by
various stimuli [25,26]. Moreover, the cell adhesion mol-
ecule CEACAM1 is involved in intercellular adhesion and
subsequent signal transduction events in a number of epi-
thelia. CEACAM1 downregulation is evident in colorectal
[27] and prostate [28] carcinomas; and the expression of
CEACAM1 in prostate cancer cells suppresses their growth
in vivo due to inhibition of tumor angiogenesis [29]. Nev-
ertheless, CEACAM1 has recently received considerable
interest as a cancer antigen target. Preclinical studies in
melanomas show that expression of the cell adhesion
molecule, CEACAM1, is an independent factor of the
metastasis risk, with a predictive value superior to that of
tumor thickness. Moreover, specific CEACAM1 gene
mutation inhibits the invasive growth of melanomas, and
Specificity test on transfectant cell lines Figure 6
Specificity test on transfectant cell lines. Binding profiles of scFv E8 on BOSC23 cells transiently transfected with 
CEACAM gene family members are shown. Blue: anti-G.O. negative control antibody; Red: positive control mAb; Green: anti-
CEA E8 scFv.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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treatment with anti-CEACAM monoclonal antibodies
blocks CEACAM1-enhanced cell invasion and cell migra-
tion in a dose-dependent manner [30]. In fact, clinical
studies in a 10-year follow-up indicate that expression of
the cell adhesion molecule CEACAM1 in primary tumors
in melanoma patients is associated with the subsequent
development of metastatic disease [31]. CEACAM1 also
appears to be a promising endothelial target for bladder
cancer therapy; this molecule is involved in the switch
from noninvasive and nonvascularized to invasive and
vascularized bladder cancer [32]. Furthermore,
CEACAM1, which is not expressed in the lung, has been
identified in 2/3 of primary adenocarcinomas from this
tissue and is considered a significant independent prog-
nostic factor for survival [33].
Detailed analysis of E8 scFv specificity on normal tissue
and cells, including skin samples, liver and neutrophils
known for CEACAM1 expression, does not reveal any
non-specific reactivity of the antibody, probably because
of lower expression levels of CEACAM1 in normal tissue
or non-stimulated neutrophils.
In comparison with many other anti-CEA antibodies, E8
is a completely human single-chain antibody of quite
high affinity. To our knowledge, this is the first anti-CEA
antibody isolated from a synthetic human scFv antibody
library, thus indicating the recombinant antibody
approach as an effective method for selection of poten-
tially useful therapeutic antibodies. Due to its particular
capacity to recognize CEACAM1 and CEACAM5 shared
epitope, E8 recognizes a large panel of tumors (colon,
breast and lung carcinomas and metastastic melanoma),
and strongly binds tumors, such as lung carcinoma, that
overexpress both the CEA proteins.
Spectral confocal microscopy of metastatic melanoma cells  stained with E8 scFv antibody Figure 8
Spectral confocal microscopy of metastatic melanoma cells 
stained with E8 scFv antibody.
Binding profiles of the scFv E8 on human cell types Figure 7
Binding profiles of the scFv E8 on human cell types. 
Dark line indicates level of reactivity of E8 and dashed line 
represents background binding level of the negative control 
scFv directed to glucose oxidase.BMC Cancer 2006, 6:41 http://www.biomedcentral.com/1471-2407/6/41
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Conclusion
The data reported and discussed in this paper indicate that
this new immunoreagent meets several criteria for a
potential anticancer compound: it is human, hence
poorly or not immunogenic; it binds selectively and with
good affinity to a CEA epitope expressed on human
tumors, including melanoma, metastatic melanoma,
lung, breast and colon carcinomas. It is particularly inter-
esting that there is no reactivity in various normal human
cells, including distinct classes of lymphocyte subpopula-
tions and neutrophils, as well as a broad panel of human
organs. While these findings propose scFv E8 for target
therapy and diagnosis of solid tumors, further anticancer
utilization of such a specific antibody, including direct
inhibition of tumor cell proliferation and metastasiza-
tion, needs to be carefully investigated.
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